Finn
NTRA Diagnostics · Genetic testing · Oncology · High growth · Thesis updated November 8, 2026

Signatera volume surges as new cancer approvals boost growth

01 Running thesis

Cancer testing is pulling the story

Natera continued its explosive growth in Q3 2026. Total tests processed hit 1.1 million. Oncology units processed reached 316,000, adding a record 33,000 sequentially. This performance led management to set a long-term target of $6 billion in revenue by 2029.

The bull case relies heavily on Signatera. This test looks for tiny traces of cancer DNA after treatment, which doctors call molecular residual disease. It recently secured Medicare coverage for early-stage liver cancer surveillance and FDA breakthrough status for early cancer detection.

The next layer of the bull case is global expansion. Signatera received regulatory approval in Japan, setting up a launch there. Management estimates this could effectively double the annual colorectal cancer volume market opportunity for the test.

The bear case is mostly confined to legal risk. Natera has about $349 million of adverse patent verdicts from Ravgen and Guardant Health that it is appealing. With operational growth blowing past expectations, the primary investment question is whether execution can consistently outweigh this specific legal and financial risk.

Nov 2026▲Q3 2026 results showed 1.1 million total tests and 316,000 Signatera units. Management set a $6 billion revenue target for 2029 and announced Solomon Moshkevich will replace Steve Chapman as CEO.
Aug 2026▲Q2 2026 results showed blowout growth with a record 34,000 sequential clinical MRD unit adds. Signatera secured FDA companion diagnostic and Japan PMDA approvals, driving a $100 million revenue guidance raise.
May 2026→The Q1 2026 10-Q confirmed the strong start already described on the earnings call. It showed about 258,900 oncology units processed, up from about 167,700 a year earlier, with no new major risk added.
May 2026▲Q1 results showed faster Signatera adoption, about 24,000 sequential clinical oncology unit adds, and a revenue guidance raise of more than $120 million. Management also pointed to Japan as a new growth path.
Feb 2026▲The 2025 10-K reduced the near-term LDT regulatory threat after the FDA rule was vacated. It also made the patent verdict risk clearer, with about $349 million tied to Ravgen and Guardant Health.
Feb 2026▲Q4 2025 showed another record Signatera quarter and positive cash flow for 2025. The Foresight Diagnostics acquisition and Latitude submission added new tools to the oncology portfolio.
Nov 2025→The Q3 2025 10-Q confirmed the strong oncology unit growth already discussed on the earnings call. It did not add a new business model change or risk.
Nov 2025▲Q3 2025 raised the growth bar again, with more than 21,500 sequential MRD unit adds and a large full-year guidance increase. New bladder cancer evidence strengthened the Signatera case.
02 Business model

Labs, insurers, and test volume

Natera makes money by selling diagnostic tests. Most tests are run in its certified labs, mainly in Austin, Texas and San Carlos, California. The company bills clinics, lab partners, patients, drug companies, and insurance payers.

The key payers are insurers. Natera says most revenue comes from insurers with in-network contracts. That gives the company more predictable payment, but the contracted price is usually below the list price. Growth depends on more doctors ordering tests, more payer coverage, and better average selling prices.

Natera also runs Constellation, a cloud model for partner labs. In that setup, another lab does the wet lab work and uses Natera software algorithms. Natera gets lower revenue per test, but it also avoids much of the processing cost.

The model scales well when volumes rise faster than sales and lab costs. That is what bulls see in Signatera today. It can break if reimbursement weakens, if doctors stop ordering more tests, or if legal costs force a large cash payment.

03 Product portfolio

Pregnancy roots, cancer engine

Growth engine

Signatera

Signatera is a personalized MRD test for cancer patients. It is the primary growth engine and recently secured FDA companion diagnostic and Japan approvals.

Cash cow

Panorama

Panorama is a non-invasive prenatal test. The company recently launched an enhanced version specifically validated for low fetal fraction patients.

Cash cow

Horizon

Horizon is a carrier screening test used in women's health. Along with Panorama, it forms the mature base of the business.

Option

Latitude

Latitude is a tissue-free MRD test for colorectal cancer. It could expand the company reach because it does not need a tumor tissue sample.

Option

Fetal Focus

Fetal Focus is a single-gene prenatal test that was expanded to 21 genes. It adds a new layer to the women's health franchise.

Steady

Prospera

Prospera tests for transplant rejection in kidney, heart, and lung patients. It gives Natera a smaller but useful organ health footprint.

Option

Constellation

Constellation licenses bioinformatics tools to other labs through the cloud. Revenue per test is lower, but so are processing costs.

04 Business segments

Mostly U.S. direct selling

U.S. direct sales force96%growing fast
U.S. lab distribution partners3%modest
International partners and sales1%flat

Natera reports one operating segment. Based on historic disclosures, revenue leans heavily on the U.S. direct sales force, with minimal international share pending the upcoming Japan launch.

05 Risk factors

What could go wrong

Patent verdict cash hit

High impact · Medium odds

Natera has adverse 2024 jury verdicts of $57 million from Ravgen and more than $292 million from Guardant Health. The total is about $349 million before any appeal outcome or other legal changes. This could materially reduce cash and hurt investor confidence.

We watchAppeal rulings, settlement news, or changes to legal accruals tied to Ravgen and Guardant Health.

Signatera volume slows

High impact · Medium odds

The bull case depends on Signatera staying on a very fast adoption curve. Management reported 33,000 sequential clinical oncology unit adds in Q3 2026. If that pace drops significantly, the market may question the long-term growth story.

We watchQuarterly clinical oncology units and whether sequential adds stay near recent record levels.

CEO transition risk

Medium impact · Low odds

Steve Chapman is stepping down as CEO and handing the role to Solomon Moshkevich. While he is an internal veteran, leadership transitions can sometimes cause operational shifts or changes in spending priorities.

We watchManagement commentary on strategy changes or any disruption in short-term sales execution.

Coverage and pricing disappoint

High impact · Medium odds

Natera needs payer coverage and good average selling prices to turn test volume into profit. MolDx decisions on expanded Signatera submissions could add upside, but delays or lower payments would cap the benefit.

We watchMolDx coverage decisions for expanded cancer types and management commentary on average selling prices.

Japan launch execution

Medium impact · Medium odds

Management expects a broad Japan launch for Signatera. It says Japan could effectively double the annual colorectal cancer volume market opportunity. That upside depends on reimbursement, local sales execution, and doctor adoption.

We watchJapan reimbursement levels and early post-launch test volumes in late 2026 and 2027.
06 Quick answers

In one breath

What does Natera do?

Natera sells DNA-based diagnostic tests. Its biggest areas are women's health, cancer monitoring, and organ transplant health.

Why is Signatera important to Natera stock?

Signatera is the main growth driver. It helps detect tiny traces of cancer DNA after treatment. In Q3 2026, it processed 316,000 clinical oncology units and secured key new coverage milestones.

What is the biggest risk for Natera?

The clearest single risk is the patent litigation overhang. Natera is appealing adverse verdicts tied to Ravgen and Guardant Health that total about $349 million.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Natera Q3 2026 Form 10-Q and Earnings Transcript
  2. Natera Q2 2026 Form 10-Q
  3. Natera 2025 Form 10-K
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Natera, Inc. in Finn's Diagnostics & Research industry ranking.

Get started with Finn today